Back
Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
ST. Holgate, H. Arshad, P. Stryszak, JE. Harrison
J. Allergy Clin. Immunol. 2000 May;105(5):906-11.
PubMed: 10808170
Abstract
Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma. To test the lower range of the dose-response curve, effects of MF delivered by dry powder inhaler (DPI) on AMP-induced bronchoconstriction were compared with those of placebo. In a placebo-controlled, 3-phase cross-over, single-center, double-blind study, 15 patients with mild asthma were randomized to three 2-week treatment phases (separated by 4-week washout phases) with MF DPI 50 microg twice daily, MF DPI 100 microg twice daily, or placebo. AMP challenge was performed before and at the end of each treatment phase. Thirteen patients completed all 3 phases and were included in the primary efficacy analysis. Treatment with MF DPI 50 microg twice daily or with MF DPI 100 microg twice daily significantly reduced the bronchoconstrictor response to AMP, displacing the dose-response curve to the right by 2.81 and 3.11 doubling dilutions, respectively, compared with placebo (P
Associated compounds:
Compound Name
with link to compound page |
Structure | Number of references |
---|---|---|
Adenosine 5'-monophosphate | 92 |